August 14, 2018

First Successful Use of a Patient-Derived Xenograft (PDX) Model to Guide Cancer Treatment

Predicts drug response in patient with rare, aggressive cancer

Patient-derived xenograft (PDX) models (immunodeficient mice engrafted with patients’ cancerous cells or tissues) have significantly enhanced cancer research in recent years. However, using PDX models to meet the urgent need for human cancer models to reliably predict clinical activity has proved challenging. Most cancer patients can’t wait months for the cells to become engrafted and grow and be used to test multiple drugs.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The average cancer grows too slowly to use PDX models to guide clinical decision-making. The patient will have received treatment long before the engraftment is ready for testing,” says Mohamed E. Abazeed, MD, PhD, a clinician and researcher in Cleveland Clinic’s Departments of Translational Hematology Oncology Research and Radiation Oncology.

Case study

At Cleveland Clinic, a 49-year-old female patient with metastatic clear cell adenocarcinoma of müllerian origin (an aggressive cancer that usually affects the cervix, endometrium and fallopian tubes and tends to disseminate rapidly), met the criteria for PDX-guided treatment: frequent upfront surgery providing ample donor tissue, rapid tumor proliferation and the absence of a definitive standard of care. A case study of her treatment appears in Precision Oncology.

At the time of diagnosis, the clear cell adenocarcinoma, which had originated in the small bowel, had metastasized to her liver and omentum. The median survival estimate is only several months for patients at a similar stage of the disease.

Several hours after her liver metastectomy, tissue was implanted into a mouse. Within 10 days, a tumor with the histopathologic features of clear cell adenocarcinoma developed. “By selecting cancers that grow aggressively, we can potentially develop PDX models in a timeframe that is clinically actionable,” says Dr. Abazeed, case study co-author with Roberto Vargas, MD, and Robert DeBernardo, MD, of the Gynecologic Oncology Division, Ob/Gyn & Women’s Health Institute. In the Cleveland Clinic inventory of 220 PDXs derived from multiple cancer types, 5.3 percent of successfully generated PDX have been harvested within two weeks of implantation, suggesting that the experimental design can be expanded to other rapidly proliferating cancers.

Genome-wide gene expression profiling showed high transcriptomic concordance of the matched donor tumor and the PDX. ERBB2 gene amplification was identified in the PDX and the levels of ERBB2 mRNA in the PDX and primary tumor were similar. These data indicated high genomic fidelity between the PDX and the donor tumor.

Advertisement

Clinical course and molecular profiling of the primary tumor. a Computed tomography scan obtained at the time of diagnosis. The 8.2 × 8.8 cm lobulated metastatic mass in the liver (arrow) and the 8.0 cm centrally necrotic primary tumor mass in the left mesentery (asterisk) are shown. b Representative image of an H&E stained section of the primary tumor. c Copy number count estimates from both exonic (blue) and intragenic or intronic (cyan) reads in Chromosome 17 are shown. d Representative FISH image of the primary tumor using ERBB2/CEP17 dual-color probes. The average ERBB2 signal copy number was 5.1 and the ERBB2/CEP17 ratio was 2.0. e Representative ErbB2 IHC image of the primary tumor. f Sagittal and coronal images of the PET/CT scans before and after treatment with three cycles of paclitaxel and neratinib (second-line treatment). The SUV maximum value for each lesion before and after treatment was, respectively: right lateral abdominal wall musculature, 11.7 and 6.6; posterior 11th rib, 11.2 and 4.1; and the soft tissue abutting the hepatic surgical site, 14.8 and 7.9. Originally published in Precision Oncology under license http://creativecommons.org/licenses/by/4.0/.]

Postoperative treatment

Following the patient’s surgeries, CT scans revealed new right inguinal lymphadenopathy, an enlarging right chest wall mass (separate from the area of resection) and an abdominal incisional recurrence, indicating widespread metastatic disease.

The patient’s postoperative recovery allowed time to seek guidance from a multidisciplinary tumor board, who recommended the combination of nivolumab with either cisplatin, gemcitabine or an anti-ErbB2 agent. After initial engraftment, the PDX was implanted into 12 mice representing these four treatment cohorts. The PDX study indicated that the gemcitabine combination was the most effective at preventing tumor growth.

The patient ultimately received the combination of gemcitabine and nivolumab. In the third round of treatment in the PDX, progression was noted in one of the three mice. The treatment resistance was confirmed, and genetic testing showed that resistance was associated with gene expression changes that have been previously implicated in several classes of chemotherapeutics, including gemcitabine.

After five cycles of therapy (five months), the patient demonstrated a partial response in all known sites of disease and no evidence of new lesions. However, soon afterwards, as predicted by the PDX, the disease progressed to the perihepatic region, the right chest wall, the right lateral abdominal wall musculature and the brain.

Advertisement

Second-line treatment and survival

Based on the results of another round of testing on the resistant PDXs, the patient received second-line treatment with concurrent paclitaxel with neratinib. She is alive with minimal residual disease 24 months past diagnosis, far longer than the average prognosis. “Using the PDX model, we were able to prospectively predict the patient’s response to first-line therapy and identify the most optimal second-line therapy,” says Dr. Abazeed.

An NIH-funded follow-up study is in the works. It will randomize patients to avatar-directed or standard- of-care therapy and compare outcomes. “We’re very excited about applying our avatar models to improve response rates in aggressive cancer types that have had very few advances in care. If we can even marginally improve the response rates for these generally recalcitrant tumors, that would represent a very significant advance for patients and their outcomes,” says Dr. Abazeed.

Related Articles

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad